NCT05523128View on ClinicalTrials.gov

The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients.

NARecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 29, 2022

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Hemophilia A
Interventions
GENETIC

ZS802

A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor VIII variant. The dose levels are as follows: 1. 2.0×10\^13vg/kg; 2. 6.0×10\^13vg/kg.

Trial Locations (1)

Unknown

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER